Holly K. Tabor, PhD and Aaron Goldenberg, PhD, MPH
Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.
AMA J Ethics. 2018;20(9):E834-840. doi:
10.1001/amajethics.2018.834.
Rebekah Davis Reed, PhD, JD and Erik L. Antonsen, PhD, MD
Though the National Aeronautics and Space Administration’s collection of disaggregated genetic data for occupational surveillance and research raises numerous privacy concerns, the Genetic Information Nondiscrimination Act of 2008 allows genetic information to be used to develop personal pharmaceuticals.
AMA J Ethics. 2018;20(9):E849-856. doi:
10.1001/amajethics.2018.849.
Pathologists should work cooperatively with clinicians and provide guidance about appropriate testing to uphold the medical ethics principle of justice.
AMA J Ethics. 2016;18(8):793-799. doi:
10.1001/journalofethics.2016.18.8.ecas5-1608.
Patient safety is a medical ethics issue that must be addressed through health care teams’ open communication as well as through time-outs and checklists.
AMA J Ethics. 2016;18(9):925-932. doi:
10.1001/journalofethics.2016.18.9.stas1-1609.
Dr Catherine V. Caldicott joins Ethics Talk to discuss why turfing, despite being such a common, troublesome ethical issue, receives such little attention in the literature, how clinicians can ensure appropriate and safe transfers of care, and what health professions students and trainees can do to confront turfing when they see it.